An H-alpha survey of the rich cluster A1689

(Abridged) We present results of an H-alpha survey in the rich cluster A1689 at z=0.18, using the LDSS++ spectrograph on the AAT. We obtained spectra covering redshifted H-alpha for 522 galaxies brighter than I=22.5, covering a field of 8.7'X8.7'. We detect H-alpha emission in 46 of these galaxies; accounting for selection effects due to sampling and cluster membership, we determine that 24% of cluster members brighter than M_R=-16.5+5log(h) are detected with H-alpha flux greater than 4h^{-2}X 10^{38} ergs/s. This corresponds to a limiting star formation rate of 0.008 h^{-2} Msun/yr, assuming 1 magnitude of dust extinction. From a Hubble Space Telescope mosaic covering 7.5' X 10.0', we determine morphologies for 199 galaxies brighter than I=21, and find that 20% of the cluster members are of type Sa or later. More than 90% of cluster spirals show H-alpha emission, compared with less than 10% of E and S0 galaxies. The cluster H-alpha luminosity function has a low normalisation relative to the z~0.2 field, by ~50%, after accounting for the different fraction of spiral galaxies in the two environments. When compared with local field galaxies, this suggests that star formation activity is suppressed in early-type cluster galaxies, relative to their field counterparts. Our sample includes 29 galaxies previously observed with ISOCAM at 6 and 15 microns. We detect all 15-micron sources at H-alpha, so there is no evidence for any star formation completely hidden at H-alpha. Comparing the 15-micron and H-alpha fluxes, we find evidence that some mid-infrared-detected galaxies could be obscured by as much as 3 magnitudes of extinction at H-alpha, although this depends on the largely unknown contribution from any AGN-heated dust to the mid-infrared flux.Comment: MNRAS - resubmitted after referee report, March 1

The effect of environment on star forming galaxies at redshift 1 - First insight from PACS

We use deep 70, 100 and 160 um observations taken with PACS, the Photodetector Array Camera and Spectrometer on board of Herschel, as part of the PACS Evolutionary Probe (PEP) guaranteed time, to study the relation between star formation rate and environment at redshift ~ 1 in the GOODS-S and GOODS-N fields. We use the SDSS spectroscopic catalog to build the local analog and study the evolution of the star formation activity dependence on the environment. At z ~ 1 we observe a reversal of the relation between star formation rate and local density, confirming the results based on Spitzer 24 um data. However, due to the high accuracy provided by PACS in measuring the star formation rate also for AGN hosts, we identify in this class of objects the cause for the reversal of the density-SFR relation. Indeed, AGN hosts favor high stellar masses, dense regions and high star formation rates. Without the AGN contribution the relation flattens consistently with respect to the local analog in the same range of star formation rates. As in the local universe, the specific star formation rate anti-correlates with the density. This is due to mass segregation both at high and low redshift. The contribution of AGN hosts does not affect this anti-correlation, since AGN hosts exhibit the same specific star formation rate as star forming galaxies at the same mass. The same global trends and AGN contribution is observed once the relations are studied per morphological type. We study the specific star formation rate vs stellar mass relation in three density regimes. Our data provides an indication that at M/M_{\odot} > 10^{11} the mean specific star formation rate tends to be higher at higher density, while the opposite trend is observed in the local SDSS star forming sample.Comment: 10 pages, 16 figures, accepted for publication on A&

Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation therapy oncology group randomized clinical trial 9910

Purpose To determine whether prolonged androgen suppression (AS) duration before radiotherapy improves survival and disease control in prostate cancer. Patients and Methods One thousand five hundred seventy-nine men with intermediate-risk prostate cancer were randomly assigned to 8 weeks of AS followed by radiotherapy with an additional 8 weeks of concurrent AS (16 weeks total) or to 28 weeks of AS followed by radiotherapy with an additional 8 weeks of AS (36 weeks total). The trial sought primarily to detect a 33% reduction in the hazard of prostate cancer death in the 28-week assignment. Time-to-event end points are reported for up to 10 years of follow-up. Results There were no between-group differences in baseline characteristics of 1,489 eligible patients with follow-up. For the 8- and 28-week assignments, 10-year disease-specific survival rates were 95% (95% CI, 93.3% to 97.0%) and 96% (95% CI, 94.6% to 98.0%; hazard ratio [HR], 0.81; P = .45), respectively, and 10-year overall survival rates were66%(95% CI, 62.0% to 69.9%) and67%(95% CI, 63.0% to 70.8%; HR, 0.95; P = .62), respectively. For the 8- and 28-week assignments, 10-year cumulative incidences of locoregional progression were 6% (95% CI, 4.3% to 8.0%) and 4% (95% CI, 2.5% to 5.7%; HR, 0.65; P = .07), respectively; 10-year distant metastasis cumulative incidences were 6% (95% CI, 4.0% to 7.7%) and 6% (95% CI, 4.0% to 7.6%; HR, 1.07; P = .80), respectively; and 10-year prostate-specific antigen-based recurrence cumulative incidences were 27% (95% CI, 23.1% to 29.8%) and 27% (95% CI, 23.4% to 30.3%; HR, 0.97; P = .77), respectively. Conclusion Extending AS duration from 8 weeks to 28 weeks before radiotherapy did not improve outcomes. A lower than expected prostate cancer death rate reduced ability to detect a between-group difference in disease-specific survival. The schedule of 8 weeks of AS before radiotherapy plus 8 weeks of AS during radiotherapy remains a standard of care in intermediate-risk prostate cancer

SHARDS: stellar populations and star formation histories of a mass-selected sample of 0.65 < z < 1.1 galaxies

We report on results from the analysis of a stellar mass-selected (log (M*/M⊙) ≥ 9.0) sample of 1644 galaxies at 0.65 11, in agreement with downsizing scenarios

The XXL Survey XIX. A realistic population of simulated X-ray AGN: Comparison of models with observations

Modern cosmological simulations rely heavily on feedback from active galactic nuclei (AGN) in order to stave off overcooling in massive galaxies and galaxy groups and clusters. An important independent test is whether or not the simulations capture the broad demographics of the observed AGN population. Here, we have used the cosmo-OWLS suite of cosmological hydrodynamical simulations to produce realistic synthetic catalogs of X-ray AGN out to $z$=3, with the aim of comparing the catalogs to the observed X-ray AGN population in the XXL survey and other recent surveys. We focused on the unabsorbed X-ray luminosity function (XLF), the Eddington ratio distribution, the black hole mass function, and the projected clustering of X-ray AGN. To compute the unabsorbed XLF of the simulated AGN, we used recent empirically-determined bolometric corrections. We show that the simulated AGN sample accurately reproduces the observed XLF over 3 orders of magnitude in X-ray luminosity in all redshift bins. To compare to the observed Eddington ratio distribution and the clustering of AGN, we produced detailed 'XMM-Newton-detected' catalogs of the simulated AGN. This requires the production of synthetic X-ray images extracted from light cones of the simulations that fold in the relevant instrumental effects of XMM-Newton. We apply a luminosity- and redshift-dependent obscuration function for the AGN and employ the same AGN detection algorithm as used for the real XXL survey. We demonstrate that the detected population of simulated AGN reproduces the observed Eddington ratio distribution and projected clustering from XXL quite well. We conclude that the simulations have a broadly realistic population of AGN and that our synthetic X-ray AGN catalogs should be useful for interpreting additional trends and as a helpful tool for quantifying AGN contamination in galaxy group and cluster X-ray surveys

Advances in structure elucidation of small molecules using mass spectrometry

The structural elucidation of small molecules using mass spectrometry plays an important role in modern life sciences and bioanalytical approaches. This review covers different soft and hard ionization techniques and figures of merit for modern mass spectrometers, such as mass resolving power, mass accuracy, isotopic abundance accuracy, accurate mass multiple-stage MS(n) capability, as well as hybrid mass spectrometric and orthogonal chromatographic approaches. The latter part discusses mass spectral data handling strategies, which includes background and noise subtraction, adduct formation and detection, charge state determination, accurate mass measurements, elemental composition determinations, and complex data-dependent setups with ion maps and ion trees. The importance of mass spectral library search algorithms for tandem mass spectra and multiple-stage MS(n) mass spectra as well as mass spectral tree libraries that combine multiple-stage mass spectra are outlined. The successive chapter discusses mass spectral fragmentation pathways, biotransformation reactions and drug metabolism studies, the mass spectral simulation and generation of in silico mass spectra, expert systems for mass spectral interpretation, and the use of computational chemistry to explain gas-phase phenomena. A single chapter discusses data handling for hyphenated approaches including mass spectral deconvolution for clean mass spectra, cheminformatics approaches and structure retention relationships, and retention index predictions for gas and liquid chromatography. The last section reviews the current state of electronic data sharing of mass spectra and discusses the importance of software development for the advancement of structure elucidation of small molecules

Correction to: Two years later: Is the SARS-CoV-2 pandemic still having an impact on emergency surgery? An international cross-sectional survey among WSES members

Background: The SARS-CoV-2 pandemic is still ongoing and a major challenge for health care services worldwide. In the first WSES COVID-19 emergency surgery survey, a strong negative impact on emergency surgery (ES) had been described already early in the pandemic situation. However, the knowledge is limited about current effects of the pandemic on patient flow through emergency rooms, daily routine and decision making in ES as well as their changes over time during the last two pandemic years. This second WSES COVID-19 emergency surgery survey investigates the impact of the SARS-CoV-2 pandemic on ES during the course of the pandemic. Methods: A web survey had been distributed to medical specialists in ES during a four-week period from January 2022, investigating the impact of the pandemic on patients and septic diseases both requiring ES, structural problems due to the pandemic and time-to-intervention in ES routine. Results: 367 collaborators from 59 countries responded to the survey. The majority indicated that the pandemic still significantly impacts on treatment and outcome of surgical emergency patients (83.1% and 78.5%, respectively). As reasons, the collaborators reported decreased case load in ES (44.7%), but patients presenting with more prolonged and severe diseases, especially concerning perforated appendicitis (62.1%) and diverticulitis (57.5%). Otherwise, approximately 50% of the participants still observe a delay in time-to-intervention in ES compared with the situation before the pandemic. Relevant causes leading to enlarged time-to-intervention in ES during the pandemic are persistent problems with in-hospital logistics, lacks in medical staff as well as operating room and intensive care capacities during the pandemic. This leads not only to the need for triage or transferring of ES patients to other hospitals, reported by 64.0% and 48.8% of the collaborators, respectively, but also to paradigm shifts in treatment modalities to non-operative approaches reported by 67.3% of the participants, especially in uncomplicated appendicitis, cholecystitis and multiple-recurrent diverticulitis. Conclusions: The SARS-CoV-2 pandemic still significantly impacts on care and outcome of patients in ES. Well-known problems with in-hospital logistics are not sufficiently resolved by now; however, medical staff shortages and reduced capacities have been dramatically aggravated over last two pandemic years

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research